Advisory boards to the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) on Tuesday decided that the benefits of jabbing children between five and 11 years old with the Pfizer vaccine outweigh any other health risks.
The decision now awaits further approval from the full FDA and CDC. Both agencies are expected to follow the vaccine panel’s recommendation.
Data from the company’s clinical trials found that a paediatric dose of the vaccine – one third of that given to adults and adolescents – was safe and 90% effective.
